Charcot-Marie-Tooth disease type 2H
shahr-koh mah-ree tooth
Also known as: CMT2H, Autosomal Recessive Axonal Neuropathy
At a Glance
What is Charcot-Marie-Tooth disease type 2H?
Charcot-Marie-Tooth disease type 2H is a rare genetic disorder that affects the peripheral nervous system, which is responsible for transmitting signals from the brain and spinal cord to the rest of the body. It is caused by mutations in specific genes that are crucial for nerve function. Over time, individuals with this condition experience progressive muscle weakness and atrophy, particularly in the lower legs and feet, leading to difficulty walking. Early symptoms often include foot drop, high arches, and hammertoes, while later stages may involve hand weakness and sensory loss. Early diagnosis is critical to managing symptoms and slowing progression through physical therapy and supportive devices. The condition can significantly impact family life, as affected individuals may require assistance with daily activities and mobility. Prognosis varies, but many individuals maintain a normal life expectancy with appropriate management. Daily life can be challenging due to mobility issues, but adaptive strategies and support can enhance quality of life. CMT2H primarily affects the musculoskeletal and nervous systems, leading to a gradual decline in motor function. Genetic counseling is recommended for affected families to understand inheritance patterns and risks. Despite its challenges, many individuals with CMT2H lead fulfilling lives with the right support and interventions.
Medical Definition
Charcot-Marie-Tooth disease type 2H is an autosomal recessive axonal neuropathy characterized by mutations in the KIAA1840 gene, also known as SPG11. Pathologically, it involves degeneration of the axons in peripheral nerves, leading to muscle weakness and sensory deficits. Histological findings typically show loss of myelinated fibers and axonal degeneration. It is classified under the broader category of Charcot-Marie-Tooth disease type 2, which encompasses axonal forms of the disorder. Epidemiologically, it is a rare condition with a prevalence of approximately 1 in 250,000 individuals. The disease course is progressive, with symptoms worsening over time, although the rate of progression can vary among individuals.
Charcot-Marie-Tooth disease type 2H Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness in Charcot-Marie-Tooth disease type 2H typically begins in the lower limbs, particularly affecting the feet and ankles. This weakness is due to the degeneration of axons in peripheral nerves, which impairs signal transmission to muscles. Over time, the weakness may progress to the hands and forearms, leading to difficulties with fine motor skills. Daily life is impacted as patients may struggle with walking, balance, and performing tasks requiring manual dexterity; physical therapy and assistive devices can help manage these challenges.
Foot deformities such as high arches or hammertoes are common in individuals with this condition. These deformities arise from imbalances in muscle strength and tone due to nerve damage. As the disease progresses, these deformities can worsen, leading to increased discomfort and difficulty in finding suitable footwear. Orthotic devices and, in some cases, surgical intervention can alleviate symptoms and improve mobility.
Sensory loss often begins in the feet and hands, presenting as numbness or a tingling sensation. This occurs because the sensory nerves are also affected by the axonal degeneration characteristic of the disease. The sensory loss can progress to more proximal areas, affecting the ability to perceive temperature, pain, and touch. This can lead to injuries and ulcers due to unnoticed trauma, so regular monitoring and protective measures are essential.
Common
Gait abnormalities in patients manifest as a high-stepping walk or foot drop, where the foot drags along the ground. These abnormalities are caused by muscle weakness and foot deformities, which alter the normal walking pattern. Over time, the gait issues can lead to increased fatigue and risk of falls. Physical therapy and orthotic supports can help improve gait and reduce the risk of injury.
Hand weakness may develop as the disease progresses, affecting grip strength and dexterity. This weakness results from the degeneration of motor nerves supplying the hand muscles. As it progresses, patients may find it difficult to perform tasks such as buttoning clothes or writing. Occupational therapy and adaptive devices can assist in maintaining hand function and independence.
Muscle cramps can occur frequently, particularly in the legs, causing sudden and intense pain. These cramps are due to the disrupted nerve signals and muscle imbalances caused by the disease. They may become more frequent and severe over time, impacting sleep and daily activities. Stretching exercises, hydration, and medications can help manage and reduce the frequency of cramps.
Less Common
Some individuals may experience hearing loss, which can be sensorineural in nature. This occurs due to the involvement of cranial nerves or central auditory pathways in the disease process. Hearing loss may progress slowly and can affect communication and social interactions. Hearing aids and auditory rehabilitation can help improve hearing and quality of life.
Breathing difficulties can arise due to weakness of the respiratory muscles. This is a result of the progressive nature of the disease affecting the muscles involved in breathing. Over time, this can lead to reduced lung capacity and respiratory complications, particularly during sleep. Respiratory therapy and, in severe cases, mechanical ventilation support may be necessary to manage these symptoms.
What Causes Charcot-Marie-Tooth disease type 2H?
Charcot-Marie-Tooth disease type 2H is primarily caused by mutations in the KIF1B gene, located on chromosome 1p36.22. The KIF1B gene encodes a kinesin family member protein that is essential for axonal transport of synaptic vesicle precursors and mitochondria along microtubules. Mutations in KIF1B can lead to a defective motor protein, impairing its ability to bind to microtubules and transport cellular components efficiently. This disruption in axonal transport results in the accumulation of organelles and proteins, leading to axonal degeneration. The impaired transport affects mitochondrial distribution and function, causing energy deficits and increased oxidative stress in neurons. Neighboring cells and tissues experience secondary effects due to the loss of trophic support and increased apoptotic signaling. Neuroinflammation may be triggered as a response to neuronal injury, exacerbating the degeneration process. White matter degeneration occurs as a result of axonal loss and demyelination, contributing to the progressive nature of the disease. Symptoms typically manifest in a distal-to-proximal pattern due to the length-dependent vulnerability of peripheral nerves. Variability in disease severity among patients can be attributed to differences in mutation type, genetic background, and environmental factors. The specific pattern of muscle weakness and sensory loss is linked to the selective vulnerability of motor and sensory neurons. Additionally, the involvement of immune responses can vary, influencing the rate of disease progression. The degeneration of peripheral nerves leads to muscle atrophy and sensory deficits, characteristic of Charcot-Marie-Tooth disease. The interplay between genetic mutations and cellular stress responses determines the clinical heterogeneity observed in patients.
How is Charcot-Marie-Tooth disease type 2H Diagnosed?
Typical age of diagnosis: Charcot-Marie-Tooth disease type 2H is typically diagnosed in late childhood to early adulthood, often when patients present with progressive muscle weakness and sensory loss. Diagnosis is usually prompted by clinical symptoms and family history suggestive of a hereditary neuropathy.
Clinicians look for signs of distal muscle weakness, atrophy, and sensory loss, particularly in the lower extremities. A detailed family history is crucial to identify any hereditary patterns of neuropathy. Physical examination may reveal foot deformities such as pes cavus and reduced deep tendon reflexes. This step helps to differentiate CMT2H from other neuropathies and directs further diagnostic testing.
Magnetic Resonance Imaging (MRI) of the peripheral nerves is often used. It may show nerve enlargement or other structural abnormalities consistent with axonal degeneration. These findings support the diagnosis of CMT2H and help exclude demyelinating neuropathies. MRI can also rule out other causes of neuropathy such as compressive lesions.
Nerve conduction studies are ordered to assess the speed and strength of electrical signals in the nerves. Biomarkers such as elevated serum creatine kinase may be sought, indicating muscle damage. Abnormal results typically show reduced conduction velocities and prolonged distal latencies. These results guide the clinician toward considering genetic testing for confirmation.
Genetic testing focuses on sequencing the KIAA1840 gene, among others. Mutations such as missense or nonsense mutations are identified. The presence of these mutations confirms the diagnosis of CMT2H. Results also provide important information for family counseling regarding inheritance patterns and recurrence risks.
Charcot-Marie-Tooth disease type 2H Treatment Options
Gabapentin is an anticonvulsant drug that modulates neurotransmitter release. It is used to manage neuropathic pain associated with CMT2H. Clinical evidence suggests it can reduce pain symptoms, improving quality of life. However, it does not alter disease progression and may cause side effects such as dizziness and fatigue. Its use is limited by the need for careful dose titration and monitoring.
Physical therapy techniques include strength training and balance exercises. The goal is to improve mobility and prevent falls. Sessions are typically held 2-3 times per week, lasting 30-60 minutes each. Outcomes are measured by improved walking speed and reduced fall frequency. Long-term benefits include enhanced independence and reduced disability.
Surgery is indicated for severe foot deformities causing functional impairment. The procedure involves tendon transfers or osteotomies to correct alignment. Expected benefits include improved gait and reduced pain. Surgical risks include infection and nerve damage. Post-operative care requires physical therapy to maintain surgical outcomes.
The care team includes neurologists, physiotherapists, and occupational therapists. Interventions focus on pain management, mobility aids, and adaptive devices. Psychosocial support is provided through counseling and support groups. Family education covers disease management and genetic counseling. Long-term monitoring involves regular assessments to adjust care plans as needed.
When to See a Doctor for Charcot-Marie-Tooth disease type 2H
- Sudden inability to walk β This could indicate rapid disease progression or a secondary complication requiring immediate medical attention.
- Severe breathing difficulties β This may suggest respiratory muscle involvement, which can be life-threatening and needs urgent care.
- Loss of consciousness β This could be a sign of severe complications affecting the nervous system and requires emergency intervention.
- Progressive muscle weakness β This indicates worsening of the condition and should prompt a consultation with a neurologist.
- Persistent numbness or tingling in extremities β This may suggest nerve damage progression and warrants medical evaluation.
- Difficulty with fine motor skills β This can impact daily activities and may require occupational therapy or medical advice.
- Mild fatigue β Monitor energy levels and ensure adequate rest; consult a doctor if it worsens.
- Occasional muscle cramps β Keep track of frequency and severity; consider lifestyle modifications and consult a healthcare provider if persistent.
Charcot-Marie-Tooth disease type 2H β Frequently Asked Questions
Is this condition hereditary?
Charcot-Marie-Tooth disease type 2H is inherited in an autosomal recessive pattern. This means that both parents must carry one copy of the mutated gene to pass it to their children. De novo mutations are rare but possible. Carriers typically do not show symptoms but can pass the gene to offspring. Genetic counseling is recommended for affected families to understand risks and implications.
What is the life expectancy for someone with this condition?
Life expectancy for Charcot-Marie-Tooth disease type 2H can vary depending on the severity and age of onset. Early onset may lead to more severe disability, while later onset often results in a milder course. Mortality is usually due to complications such as respiratory failure. Treatment and supportive care can improve quality of life and potentially extend survival. Realistic expectations should include managing symptoms and maintaining independence as much as possible.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months to years. Neurologists and geneticists are typically consulted during the diagnostic process. Delays can occur due to the rarity of the condition and overlapping symptoms with other neuropathies. Genetic testing confirms the diagnosis by identifying specific mutations.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and novel drug approaches showing promise. Clinical trials are exploring various treatments, and information can be found on ClinicalTrials.gov. Patients should discuss potential trials with their doctors to understand eligibility and benefits. New treatments may take years to become widely available. Staying informed about research developments is crucial for accessing future therapies.
How does this condition affect daily life and activities?
Charcot-Marie-Tooth disease type 2H can significantly impact mobility and self-care, requiring assistive devices. Educational accommodations may be necessary for children with the condition. Social and emotional challenges include coping with physical limitations and potential isolation. Family members often face increased caregiving responsibilities. Supportive measures such as physical therapy and community resources can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Sleep disorders in Charcot-Marie-Tooth disease type 1.
Boentert M, Knop K, Schuhmacher C et al. Β· J Neurol Neurosurg Psychiatry Β· 2014 Β· PMID: 23704315
- 2.ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease.
Montecchiani C, Pedace L, Lo Giudice T et al. Β· Brain Β· 2016 Β· PMID: 26556829
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-18